CATALYST Logo - JPG 2016-01-20

Phase 3 CATALYST Trial of Bardoxolone Methyl in CTD-PAH Patients

Reata announced on October 6, 2016 that it has enrolled the first patient into its Phase 3 trial (CATALYST) to evaluate the efficacy and safety of bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH).